...
首页> 外文期刊>Clinical ophthalmology >Refractive outcomes and safety of the implantable collamer lens in young low-to-moderate myopes
【24h】

Refractive outcomes and safety of the implantable collamer lens in young low-to-moderate myopes

机译:植入抗溶镜镜头在年轻低于中度近视的折射结果和安全性

获取原文

摘要

Purpose: To evaluate visual and refractive outcomes and safety of implantable collamer lens (ICL) implantation in low-to-moderate myopia. Setting: Private Practice – Dougherty Laser Vision, Westlake Village, CA, USA. Methods: A chart review was performed in 56 (104 eyes) consecutive patients who underwent implantation of the Visian ICL V4 model. Inclusion criteria were age between 21 and 40 years, spherical equivalent between -3.00 D and -10.00 D, and cylinder up to -5 D. Data on visual acuity, refraction, and complications were collected. Results: The mean time to the last postoperative visit was 13.1±14.0 months (range, 2 to 50 months). The mean preoperative spherical equivalent was -6.96±1.60 D and the mean preoperative cylinder was -1.03±0.88 D. The mean preoperative corrected distance visual acuity (CDVA) was 20/20 (range, 20/15 to 20/80) that remained unchanged at last postoperative visit. At the last postoperative visit, the spherical equivalent was -0.08±0.01 D and the cylinder was 0.29±0.71 D. Comparison of postoperative uncorrected distance visual acuity (UCDVA) to preoperative CDVA indicated that 27 eyes (26%) had better postoperative UCDVA and 61 eyes (59%) had UDVA equivalent to the preoperative CDVA. Postoperatively, 4 eyes lost 1 line of CDVA and no eyes lost >1 line of CDVA. There were 32 eyes that gained at least ≥1 of CDVA. There were no intraoperative complications. Postoperatively, 3 patients (6 eyes) had dry eye, and 1 patient complained of nighttime halos in 1 eye. At the last postoperative visit, there were no eyes with lens opacity or glaucoma. Conclusion: ICL implantation for low and moderate myopia up to -10 D in patients up to 40 years of age was safe, accurate, and efficacious. ICL implantation may be a good alternative to laser in situ keratomileusis for young myopes less than -10.00 D.
机译:目的:评估低于中度近视的可植入抗溶孔晶状体(ICL)植入的视觉和屈光结果和安全性。环境:私人实践 - Dougherty Laser Vision,Westlake Village,USA,USA。方法:在56名(104只眼睛)的连续患者中进行了图表审查,该患者进行了植入Visian ICL V4模型。纳入标准年龄在21至40岁之间,球形当量在-3.00d和-10.00d之间,以及最高可达-5 d的气缸。收集视力,折射和并发症的数据。结果:最后一次术后访问的平均时间为13.1±14.0个月(范围,2至50个月)。平均术前球形等同物为-6.96±1.60d,平均术前气缸为-1.03±0.88 d。平均术前矫正距离视力(CDVA)为20/20(范围,20/15至20/80)仍然存在在最后术后访问不变。在最后的术后访问时,球形当量为-0.08±0.01d,气缸为0.29±0.71 d。术后未矫正距离视力(UCDVA)对术前CDVA的比较表明,27只眼(26%)术后术后UCDVA更好61只眼(59%)有UDVA等同于术前CDVA。术后,4只眼睛丢失了1行CDVA,没有眼睛丢失> 1线CDVA。有32只眼睛获得至少≥1个CDVA。没有术中并发症。术后,3名患者(6只眼)有干眼症,1例患者抱怨1只眼中。在最后的术后访问中,没有眼睛没有透镜不透明度或青光眼。结论:在40岁以下的患者中,ICL植入高达-10d至-10d,可安全,准确,有效。 ICL植入可能是激光原位角膜瘤的替代品,对于小于-10.00d的年轻米宫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号